Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: Acid reflux, bile reflux, or both?

American Journal of Gastroenterology

Volumn 99, Issue 6, 2004, Pages 981-988

  Tack, Jan ^a   Koek, G ^a   Demedts, I ^a   Sifrim, D ^a   Janssens, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AMBULATORY MONITORING; ARTICLE; BARRETT ESOPHAGUS; BILE REFLUX; BILITEC MONITORING; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUODENOGASTROESOPHAGEAL REFLUX; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MANOMETRY; PATIENT MONITORING; PH MEASUREMENT; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STOMACH ACID; STOMACH ACID SECRETION; STOMACH PH;

ADULT; BARRETT ESOPHAGUS; BILE REFLUX; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; DUODENOGASTRIC REFLUX; ESOPHAGOSCOPY; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROBABILITY; PROTON PUMPS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT FAILURE;

EID: 3142691409     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.04171.x     Document Type: Article

References (45)

1. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastroesophageal reflux disease in an adult population. Ann Med 1995;27:67-70.
2. Spechler SJ. Epidemiology and natural history of gastroesophageal reflux disease. Digestion 1992;51(suppl 1):24-9.
3. Dehn TCB, Sheperd HA, Colin-Jones D, et al. Double blind comparison of omeprazole versus cimetidine in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring. Gut 1990;31:509-13.
4. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.
5. Sontag SJ, Hirwhowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study. Gastroenterology 1992;102:108-18.
6. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994;121:161-7.
7. Robinson M, Campbell DR, Sontag S, et al. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Lansoprazole, a new proton pump inhibitor. Dig Dis Sci 1995;40:590-7.
8. Earnest D, Dorsch E, Jones J, et al. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998;93:238-43.
9. Holloway RH, Dent J, Narielvala F, et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole. Gut 1996;38:649-54.
10. Klinkenberg-Knol EC, Meuwissen SGM. Combined gastric and esophageal 24-h pH monitoring and esophageal manometry in patients with reflux disease resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990;4:485-95.
11. Katzka DA, Paoletti V, Leite L, et al. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: Testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 1996;91:2110-3.
12. Fass R, Mackel C, Sampliner RE. 24-h pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment. J Clin Gastroenterol 1994;19:97-9.
13. Bechi P, Paucciani F, Baldini F, et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993;38:1297-306.
14. Vaezi MF, LaCamera RG, Richter JE. Bilitec 2000 ambulatory duodenogastric reflux monitoring system. Studies on its validation and limitations. Am J Phys 1994;267:G1050-7.
15. Stein HJ, Kauer WK, Feussner H, et al. Bile acids as components of the duodenogastric refluate: Detection, relationship to bilirubin, mechanism of injury, and clinical relevance. Hepato-gastroenterology 1999;46:66-73.
16. Stipa F, Stein HJ, Feussner H, et al. Assessment of non-acidic esophageal reflux: Comparison between long-term reflux aspiration test and fiberoptic bilirubin monitoring. Dis Esophagus 1997;10:24-8.
17. Champion G, Richter JE, Vaezi MF, et al. Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994;107:747-54.
18. Caldwell MT, Lawlor P, Byrne PJ, et al. Ambulatory oesophageal DGER monitoring in Barrett's esophagus. Br J Surg 1995;82:657-60.
19. Kauer WK, Peters JH, DeMeester TR, et al. Mixed reflux of gastric and duodenaljuices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy reemphasized. Ann Surg 1995;222:525-31.
20. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-9.
21. Vaezi MF, Richter JE. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995;117:699-704.
22. Savary M, Miller G. L'oesophage. Manuel et Atlas d'Edoscopie. Solothurn, Switzerland: Verlag Gassmann, 1977.
23. Cuomo R, Koek G, Sifrim D, et al. Analysis of ambulatory duodeno-gastro-esophageal reflux monitoring. Dig Dis Sci 2001;45:2463-9.
24. Tack J, Koek GH, Bisschops R, et al. Dietary restrictions during ambulatory monitoring of duodeno-gastro-esophageal reflux. Dig Dis Sci 2003;48:1213-20.
25. Klinkenberg-Knol E, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
26. Koek G, Vos R, Flamen P, et al. Esophageal clearance of acid and bile: A combined radionuclide, pH and Bilitec study. Gut 2004;53:21-6.
27. Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363-73.
28. Shi G, Bruley des Varannes S, Scarpignato C, et al. Reflux-related symptoms in patients with normal oesophageal exposure to acid. The acid hypersensitive esophagus. Gut 1995;37:457-64.
29. Richter JE, Kahrilas PJ, Johanson J, for the Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esohagitis: A randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
30. Koek GH, Tack J, Sifrim D, et al. The role of acid and bile reflux in symptomatic gastro-esophageal reflux disease. Am J Gastroenterol 2001;96:2033-40.
31. Wilmer A, Tack J, Frans E, et al. Duodenogastroesophageal reflux and esophageal mucosal injury in mechanically ventilated patients. Gastroenterology 1999;116:1293-9.
32. Sifrim D, Holloway R, Silny J, et al. Acid, nonacid and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-h pH-impedance recordings. Gastroenterology 2001;120:1588-98.
33. Vela M, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology 2001;120:1599-606.
34. Bradley LA, Richter JE, Pulliam TJ, et al. The relationship between stress and symptoms of gastroesophageal reflux: The influence of psychological factors. Am J Gastroenterol 1993;88:11-9.
35. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249-58.
36. Marshall RE, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-osophageal bile reflux in Barrett's esophagus. Gut 1998;43:603-6.
37. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 2001;96:331-7.
38. Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: Effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg 1998;2:333-41.
39. Vaezi MF, Sears R, Richter JE. Placebo-controlled trial of cisapride in postgastrectomy patients with duodenogastroesophageal reflux. Dig Dis Sci 1996;41:754-63.
40. Schoeman MN, Tippett MD, Akkermans LMA, et al. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 1995;108:83-91.
41. Penagini R, Schoeman MN, Dent J, et al. Motor events underlying gastro-esophageal reflux in ambulant patients with reflux esophagitis. Neurogastroenterol Mot 1996;8:131-41.
42. Sifrim D, Holloway R, Silny J, et al. Composition of the post-prandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96:647-55.
43. Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000;118:7-13.
44. Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in patients with gastrooesophageal reflux disease. Gut 2002;05:19-24.
45. Tack J, Koek GH, Sifrim D, et al. The effect of the GABAb agonist baclofen in patients with symptoms and duodenogastro-esophageal reflux refractory to proton pump inhibitors. Gut 2003;10:1397-402.